ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Kyowa Hakko Kirin Co., Ltd.

Business Summary

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2019 JPYUSD
Revenue305,820M2,805.40M
Gross Profit226,200M2,075.02M
Operating income55,373M507.95M
Income before tax44,492M408.14M
Net income37,674M345.59M
EBITDA74,170M680.39M
Diluted EPS124.451.14
Dividends Per Share420.38
Total Assets784,453M7,218.33M
Total liabilities106,203M977.25M
Total equity678,250M6,241.08M
Operating cash flow53,655M492.19M
Currency in JPYCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 364,316M 347,956M 353,380M 346,531M 305,820M
Gross Profit 201,072M 204,610M 215,972M 218,840M 226,200M
Operating income 43,765M 51,468M 62,209M 58,791M 55,373M
Income before tax 41,400M 42,877M 55,849M 73,438M 44,492M
Net income 29,774M 30,450M 42,899M 54,414M 37,674M
EBITDA 80,324M 75,252M 84,241M 81,012M 74,170M
Diluted EPS 54.36 55.59 78.30 99.29 124.45
Dividends Per Share 25 25 27 35 42
Total Assets 720,764M 683,801M 708,295M 741,982M 784,453M
Total liabilities 105,906M 106,766M 92,268M 92,361M 106,203M
Total equity 614,858M 577,036M 616,028M 649,621M 678,250M
Operating cash flow 66,526M 66,881M 64,902M 56,181M 53,655M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 3,009.26M 3,202.27M 3,151.41M 3,137.65M 2,805.40M
Gross Profit 1,660.86M 1,883.04M 1,926.02M 1,981.47M 2,075.02M
Operating income 361.50M 473.66M 554.77M 532.32M 507.95M
Income before tax 341.96M 394.60M 498.05M 664.94M 408.14M
Net income 245.93M 280.23M 382.57M 492.68M 345.59M
EBITDA 663.47M 692.55M 751.25M 733.51M 680.39M
Diluted EPS 0.44 0.51 0.69 0.89 1.14
Dividends Per Share 0.20 0.23 0.24 0.31 0.38
Total Assets 5,991.63M 5,862.74M 6,287.57M 6,762.81M 7,218.33M
Total liabilities 880.38M 915.38M 819.06M 841.82M 977.25M
Total equity 5,111.25M 4,947.36M 5,468.51M 5,920.98M 6,241.08M
Operating cash flow 549.50M 615.51M 578.79M 508.68M 492.19M

Valuation Measures

Dec 2019
PER20.65
ROA4.93%
ROE5.67%
Operating margin18.10%
Profit margin12.31%

Key executives

  • Chairman & Chief Executive Officer: Nobuo Hanai
  • President, COO & Representative Director: Masashi Miyamoto
  • Executive Officer, Manager-Accounting & Finance: Motohiko Kawaguchi
  • Executive Officer, GM-Research & Development: Mitsuo Satoh
  • Representative Director & Executive Vice President: Yutaka Osawa

Shareholders

  • Kirin Holdings Co., Ltd. (53.4%)
  • Nomura Asset Management Co., Ltd. (3.2%)
  • Nikko Asset Management Co., Ltd. (1.3%)
  • Daiwa Asset Management Co. Ltd. (1.3%)
  • The Vanguard Group, Inc. (1.2%)
  • Mizuho Bank Pension Fund (1.2%)
  • Norges Bank Investment Management (0.7%)
  • BlackRock Fund Advisors (0.7%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.6%)
  • Sumitomo Mitsui DS Asset Management Co., Ltd. (0.5%)

Contact Details

  • Website:http://www.kyowa-kirin.co.jp
  • Address: Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Tokyo, 100-0004, Japan
  • Phone: +81.3.5205.7200

Related Companies

  • Kyowa Kirin GmbH
  • Strakan International SARL
  • Kyowa Kirin Plus Co. Ltd.
  • Kyowa Hakko Bio Co. Ltd. (Beijing)
  • Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
  • Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
  • Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
  • Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
  • Kyowa Hakko Kirin (Taiwan) Co. Ltd.
  • Kyowa Hakko Kirin (Singapore) Pte Ltd.
  • Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin (Thailand) Co. Ltd.
  • ProStrakan SRL
  • Kyowa Hakko Kirin America, Inc.
  • Kyowa Hakko Kirin Korea Co., Ltd.
  • Kyowa Hakko Kirin Employee Stock Owner Ship Plan
  • Kyowa Hakko Bio Italia SRL
  • Zenmi Foods, Inc.
  • Chiyoda Kaihatsu Co., Ltd.
  • Kyowa Hakko Kirin California, Inc.
  • Kyowa Kirin International Plc
  • BioWa, Inc.

Competitors

  • Biocon Limited
  • Coherus BioSciences, Inc.
  • FibroGen, Inc.
  • arGEN-X SE
  • Genexine, Inc.
  • Miragen Therapeutics, Inc.
  • Tetralogic Pharmaceuticals Corporation
  • Insys Therapeutics, Inc.
  • Portola Pharmaceuticals, Inc.
  • Innate Pharma SA Class A
  • Seattle Genetics, Inc.
  • Dermira Inc
  • Heron Therapeutics Inc
Last Updated on 21 Feb, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media